Another study found that miR-221 expression is downregulated in a subset of gastrointestinal stromal tumors, allowing for expression of Kit, and that exogenous miR-221 could act as a putative new therapeutic agent for silencing Kit in these tumors [41]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.